The EP4-selective antagonists ONO-AE2-227 and ONO-AE3-208 are undergoing preclinical evaluation and have demonstrated promising effects inhibiting tumor growth in animal models [278,279]; nevertheless, their clinical testing and application remained limited. The gene discussed is PTGER4; the disease is neoplasm.